Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,256 across all filing types
Latest filing 2025-12-17 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2025-12-17 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying the closure of the trading window in compliance with insider trading regulations. It specifies the dates for the trading window closure around the announcement of unaudited quarterly financial results. The content is a regulatory compliance announcement related to trading restrictions, not a financial report, earnings release, or management discussion. The document length is short (1292 characters), and it does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2025-12-15 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) providing contact details of Key Managerial Personnel authorized to determine materiality of events as per SEBI regulations. It is a regulatory compliance announcement rather than a financial report or detailed filing. The document length is short (1458 characters) and it does not contain financial data, audit information, or meeting materials. It is not a report itself but an official notification to the exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-12-08 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2025-12-08 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2025-12-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.